Expanded commercial footprint Novan recently completed the acquisition of EPI Health, which provides a robust commercial infrastructure including sales, marketing, communications, market access, and pharmacy relations across 42 territories. This creates a broader platform for selling dermatology products and accelerating go-to-market efforts.

Therapeutic pipeline The company is advancing SB206 (berdazimer gel) for viral skin infections like molluscum contagiosum and operates a nitric oxide based technology platform, NITRICIL, for multiple indications. This presents multiple near-term and future sales opportunities across dermatology specialties.

Diversified product focus Post-acquisition, EPI Health’s portfolio includes plaque psoriasis, rosacea, acne, and dermatoses. These markets offer recurring prescription opportunities and potential cross-sell with Novan's existing dermatology products and channels.

Strategic partnerships Historical licensing and collaboration activity with Sato Pharmaceutical in Japan and broader international reach indicate openness to co-development and licensing deals, which can unlock joint sales channels and geographic expansion.

Financial resilience The company has secured financing and investment from Ligand Pharmaceuticals and has taken steps to manage cash, suggesting a willingness to invest in commercial expansion, launches, and field sales growth to capitalize on its pipeline and new distribution networks.